- Report
- September 2026
- 186 Pages
Global
From €3334EUR$3,545USD£2,781GBP
€3705EUR$3,939USD£3,090GBP
- Report
- March 2026
- 250 Pages
Global
From €4223EUR$4,490USD£3,523GBP
- Report
- November 2026
- 391 Pages
Global
From €5502EUR$5,850USD£4,590GBP
- Report
- August 2026
- 120 Pages
Global
From €4467EUR$4,750USD£3,727GBP
- Report
- July 2026
- 200 Pages
Global
From €7515EUR$7,990USD£6,269GBP
- Report
- January 2024
- 269 Pages
Global
From €6800EUR$7,484USD£5,481GBP
- Report
- April 2023
- 175 Pages
Global
From €5548EUR$5,899USD£4,628GBP
- Report
- March 2025
- 150 Pages
Global
From €4561EUR$4,850USD£3,805GBP
- Report
- May 2021
- 50 Pages
China
From €2445EUR$2,600USD£2,040GBP
Tazobactam is an antibiotic used in combination with other antibiotics to treat a variety of bacterial infections. It is a beta-lactamase inhibitor, which means it prevents bacteria from breaking down the antibiotics, allowing them to work more effectively. Tazobactam is often used in combination with piperacillin, a broad-spectrum antibiotic, to treat serious infections such as pneumonia, sepsis, and urinary tract infections. It is also used to treat infections caused by multi-drug resistant bacteria.
Tazobactam is available in both injectable and oral forms, and is approved for use in adults and children. It is generally well-tolerated, with few side effects. However, it can cause allergic reactions in some people.
The tazobactam market is a growing segment of the antibiotics market, as it is increasingly used to treat multi-drug resistant infections. It is also used in combination with other antibiotics to treat a variety of bacterial infections.
Some companies in the tazobactam market include Merck, Pfizer, GlaxoSmithKline, and AstraZeneca. Show Less Read more